Co-printing of vertical axis aligned micron-scaled filaments via simultaneous dual needle electrohydrodynamic printing

Baolin Wang, Shuting Wu, Zeeshan Ahmad, Jing song Li, Ming Wei Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this study dual-needle electrohydrodynamic co-printing (DN-EHDCP) was developed to fabricate unique micron-scaled architectures based on multi-material fibrous (filamentous) morphologies. Two stainless steel needles (contributing towards dual needle design) were used to simultaneously co-print poly(ɛ-caprolactone) (PCL) and polyvinylpyrrolidone (PVP) polymers (using solvent based formulations including Fe3O4 nanoparticles and active pharmaceutical ingredient (API). Differences in polymer hydrophobicity and dissolution rate were used to modulate drug release (tetracycline hydrochloride, TE-HCL) from various co-printed configurations. Optical, scanning electron and fluorescent microscopy confirmed precision alignment and vertical stacking of both PVP and PCL printed filaments. Process parameters were found to strongly influence co-print construct diameter. Fourier Transform Infrared (FTIR) spectroscopy confirmed spatial locations of both PVP and PCL filaments. TE-HCL release from co-printed formulations exhibited two phases; rapid and sustained. In vitro biological assay (using L929 cell lines) demonstrated construct biocompatibility. However, selective integration (spatial and quantity) of sacrificial PVP fibers (after rapid dissolution) provided a method of in situ void engineering for enhanced interfacial interaction for remaining PCL structures. The present study shows the development and use of simultaneously co-printed filaments in the vertical axis with potential to control drug release through alignment of individual filaments and material type. Furthermore, the use of composite matrix under an external stimulus is also demonstrated indicating multiple approaches to modulate API release.

LanguageEnglish
Pages81-89
Number of pages9
JournalEuropean Polymer Journal
Volume104
Early online date7 May 2018
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Povidone
Electrohydrodynamics
electrohydrodynamics
needles
printing
Needles
Printing
filaments
tetracyclines
Drug products
Dissolution
hydrochlorides
Tetracycline
ingredients
Pharmaceutical Preparations
Polymers
dissolving
drugs
alignment
Hydrophobicity

Keywords

  • Co-printing
  • Composite
  • Dual-needle
  • EHD printing
  • Polymer

Cite this

@article{91f3d35e62f749248ac37f8c2745a7d2,
title = "Co-printing of vertical axis aligned micron-scaled filaments via simultaneous dual needle electrohydrodynamic printing",
abstract = "In this study dual-needle electrohydrodynamic co-printing (DN-EHDCP) was developed to fabricate unique micron-scaled architectures based on multi-material fibrous (filamentous) morphologies. Two stainless steel needles (contributing towards dual needle design) were used to simultaneously co-print poly(ɛ-caprolactone) (PCL) and polyvinylpyrrolidone (PVP) polymers (using solvent based formulations including Fe3O4 nanoparticles and active pharmaceutical ingredient (API). Differences in polymer hydrophobicity and dissolution rate were used to modulate drug release (tetracycline hydrochloride, TE-HCL) from various co-printed configurations. Optical, scanning electron and fluorescent microscopy confirmed precision alignment and vertical stacking of both PVP and PCL printed filaments. Process parameters were found to strongly influence co-print construct diameter. Fourier Transform Infrared (FTIR) spectroscopy confirmed spatial locations of both PVP and PCL filaments. TE-HCL release from co-printed formulations exhibited two phases; rapid and sustained. In vitro biological assay (using L929 cell lines) demonstrated construct biocompatibility. However, selective integration (spatial and quantity) of sacrificial PVP fibers (after rapid dissolution) provided a method of in situ void engineering for enhanced interfacial interaction for remaining PCL structures. The present study shows the development and use of simultaneously co-printed filaments in the vertical axis with potential to control drug release through alignment of individual filaments and material type. Furthermore, the use of composite matrix under an external stimulus is also demonstrated indicating multiple approaches to modulate API release.",
keywords = "Co-printing, Composite, Dual-needle, EHD printing, Polymer",
author = "Baolin Wang and Shuting Wu and Zeeshan Ahmad and Li, {Jing song} and Chang, {Ming Wei}",
note = "Not open access (only paid option). Not for REF. New member of staff",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.eurpolymj.2018.05.005",
language = "English",
volume = "104",
pages = "81--89",
journal = "European Polymer Journal",
issn = "0014-3057",
publisher = "Elsevier",

}

Co-printing of vertical axis aligned micron-scaled filaments via simultaneous dual needle electrohydrodynamic printing. / Wang, Baolin; Wu, Shuting; Ahmad, Zeeshan; Li, Jing song; Chang, Ming Wei.

In: European Polymer Journal, Vol. 104, 01.07.2018, p. 81-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Co-printing of vertical axis aligned micron-scaled filaments via simultaneous dual needle electrohydrodynamic printing

AU - Wang, Baolin

AU - Wu, Shuting

AU - Ahmad, Zeeshan

AU - Li, Jing song

AU - Chang, Ming Wei

N1 - Not open access (only paid option). Not for REF. New member of staff

PY - 2018/7/1

Y1 - 2018/7/1

N2 - In this study dual-needle electrohydrodynamic co-printing (DN-EHDCP) was developed to fabricate unique micron-scaled architectures based on multi-material fibrous (filamentous) morphologies. Two stainless steel needles (contributing towards dual needle design) were used to simultaneously co-print poly(ɛ-caprolactone) (PCL) and polyvinylpyrrolidone (PVP) polymers (using solvent based formulations including Fe3O4 nanoparticles and active pharmaceutical ingredient (API). Differences in polymer hydrophobicity and dissolution rate were used to modulate drug release (tetracycline hydrochloride, TE-HCL) from various co-printed configurations. Optical, scanning electron and fluorescent microscopy confirmed precision alignment and vertical stacking of both PVP and PCL printed filaments. Process parameters were found to strongly influence co-print construct diameter. Fourier Transform Infrared (FTIR) spectroscopy confirmed spatial locations of both PVP and PCL filaments. TE-HCL release from co-printed formulations exhibited two phases; rapid and sustained. In vitro biological assay (using L929 cell lines) demonstrated construct biocompatibility. However, selective integration (spatial and quantity) of sacrificial PVP fibers (after rapid dissolution) provided a method of in situ void engineering for enhanced interfacial interaction for remaining PCL structures. The present study shows the development and use of simultaneously co-printed filaments in the vertical axis with potential to control drug release through alignment of individual filaments and material type. Furthermore, the use of composite matrix under an external stimulus is also demonstrated indicating multiple approaches to modulate API release.

AB - In this study dual-needle electrohydrodynamic co-printing (DN-EHDCP) was developed to fabricate unique micron-scaled architectures based on multi-material fibrous (filamentous) morphologies. Two stainless steel needles (contributing towards dual needle design) were used to simultaneously co-print poly(ɛ-caprolactone) (PCL) and polyvinylpyrrolidone (PVP) polymers (using solvent based formulations including Fe3O4 nanoparticles and active pharmaceutical ingredient (API). Differences in polymer hydrophobicity and dissolution rate were used to modulate drug release (tetracycline hydrochloride, TE-HCL) from various co-printed configurations. Optical, scanning electron and fluorescent microscopy confirmed precision alignment and vertical stacking of both PVP and PCL printed filaments. Process parameters were found to strongly influence co-print construct diameter. Fourier Transform Infrared (FTIR) spectroscopy confirmed spatial locations of both PVP and PCL filaments. TE-HCL release from co-printed formulations exhibited two phases; rapid and sustained. In vitro biological assay (using L929 cell lines) demonstrated construct biocompatibility. However, selective integration (spatial and quantity) of sacrificial PVP fibers (after rapid dissolution) provided a method of in situ void engineering for enhanced interfacial interaction for remaining PCL structures. The present study shows the development and use of simultaneously co-printed filaments in the vertical axis with potential to control drug release through alignment of individual filaments and material type. Furthermore, the use of composite matrix under an external stimulus is also demonstrated indicating multiple approaches to modulate API release.

KW - Co-printing

KW - Composite

KW - Dual-needle

KW - EHD printing

KW - Polymer

UR - http://www.scopus.com/inward/record.url?scp=85046790620&partnerID=8YFLogxK

U2 - 10.1016/j.eurpolymj.2018.05.005

DO - 10.1016/j.eurpolymj.2018.05.005

M3 - Article

VL - 104

SP - 81

EP - 89

JO - European Polymer Journal

T2 - European Polymer Journal

JF - European Polymer Journal

SN - 0014-3057

ER -